INS and type 2 diabetes mellitus: One clinical trial demonstrated that IDeg achieved similar improvements in glycemic control to Iglar in insulin-deficient patients with T2DM, and the day-to-day variation of fasting blood glucose was smaller in patients receiving IDeg110.